Approval · Notice of Compliance 9433 · 2008
VOLIBRIS: Notice of Compliance 9433
Issued March 20, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9433
- Date
- March 20, 2008
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Endothelin receptor antagonist
Products in this notice
Medicinal ingredients
- AMBRISENTAN 5 MG per TAB
- AMBRISENTAN 10 MG per TAB